Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clenbuterol is a sympathomimetic amine and a potent, long-acting beta2-adrenergic agonist used primarily as a bronchodilator for the treatment of asthma and other respiratory conditions in some countries outside the United States[1][3][5]. In the U.S., it is not approved for human use but is approved as Ventipulmin for treating airway obstruction in horses[1][4]. Clenbuterol acts by stimulating beta2-adrenergic receptor on bronchial smooth muscle, leading to bronchodilation. It also has decongestant properties and can increase energy expenditure, fat oxidation, and lean muscle mass while reducing body fat[6]. Due to these effects, it has been misused by athletes and bodybuilders for performance enhancement and weight loss. However, its use carries significant risks of adverse cardiovascular (e.g., tachycardia, hypertension) and neurological effects (e.g., tremors, anxiety)[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clenbuterol.